Rapport Therapeutics (RAPP)
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molec...
- Open
- 49.580
- High
- 49.900
- Low
- 48.620
- Prev. Close
- 49.010
- Volume
- 232.32K
- Turnover
- 11.44M
- Avg Price
- 49.246
- Bid/Ask Ratio
- --
- Amplitude
- 2.61%
- 52wk High
- 49.900
- Volume Ratio
- 0.87
- Turnover Ratio
- 0.73%
Rapport Therapeutics Analyst Rating
View moreForecast & Rating
Aug 19, 2026Price forecast
$62.0526.45%
Forecast & RatingStrong buy
13analysts
- Strong buy92.31%
- Buy7.69%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · 21 hours ago
Renaissance Technologies LLC Sells 109,114 Shares of Rapport Therapeutics, Inc. $RAPP
- PUBT · Aug 12 at 03:36 PM
Rapport Therapeutics CEO Abraham Ceesay sells 51,499 shares worth $2.41 million
- Market Beat · Aug 12 at 12:24 PM
Rapport Therapeutics (NASDAQ:RAPP) Given New $66.00 Price Target at HC Wainwright
- Tip Ranks · Aug 12 at 11:55 AM
Douglas Tsao Boosts Rapport Therapeutics Price Target to $66 on Strong RAP-219 Differentiation and Robust Phase 2 Data
- Market Beat · Aug 7 at 05:14 AM
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Given Average Rating of "Moderate Buy" by Brokerages
- Earnings Watch · Aug 5 at 06:18 AM
Rapport Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0
